1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability

por Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Sension, Michael, Dunbar, Megan, Gruber, Joshua, Dieterich, Douglas, Fusco, Gregory P
Publicado 2023

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens

por Mounzer, Karam, Brunet, Laurence, Fusco, Jennifer S, Mcnicholl, Ian R, Diaz Cuervo, Helena, Sension, Michael, Mccurdy, Lewis, Fusco, Gregory P
Publicado 2022

1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)

por Sinclair, Gary I, Sension, Michael, Dretler, Alexandra, Schneider, Stefan, Schubert, Catherine K, Merrill, Deanna, Richardson, David, Sherif, Bintu, Zografos, Laurie, Garris, Cindy
Publicado 2023

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort

por Sension, Michael, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Sridhar, Gayathri, Vannappagari, Vani, van Wyk, Jean A, Wohlfeiler, Michael B, Fusco, Gregory P
Publicado 2023

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort

por Hsu, Ricky K, Sension, Michael, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Sridhar, Gayathri, Vannappagari, Vani, van Wyk, Jean A, Wohlfeiler, Michael B, Fusco, Gregory P
Publicado 2023

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year

por Sension, Michael G, Hsu, Ricky K, Fusco, Jennifer S, Brunet, Laurence, Cochran, Quateka, Uranaka, Christine, Sridhar, Gayathri, Vannappagari, Vani, Zolopa, Andrew, van Wyk, Jean A, McCurdy, Lewis, Fusco, Gregory P, Wohlfeiler, Michael B
Publicado 2022

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

por Keiser, Philip H, Sension, Michael G, DeJesus, Edwin, Rodriguez, Allan, Olliffe, Jeffrey F, Williams, Vanessa C, Wakeford, John H, Snidow, Jerry W, Shachoy-Clark, Anne D, Fleming, Julie W, Pakes, Gary E, Hernandez, Jaime E
Publicado 2005